const data = [
  {
    "Trial Number": "NCT04336410",
    Developer: "Inovio Pharmaceuticals / Beijing Advaccine Biotechnology",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Estimated\r\nEnrollment": "40 participants",
    Allocation: "Non-Randomized",
    "Intervention Model": "Sequential Assignment",
    Masking: "None (Open Label)",
    "Primary Purpose": "Prevention",
    "Official Title":
      "Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",
    "Actual Study Start Date": "April 3, 2020",
    "Estimated Primary Completion Date": "April 2021",
    "Estimated Study Completion Date": "April 2021"
  },
  {
    "Trial Number": "NCT04352608",
    Developer: "Sinovac*",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Estimated\r\nEnrollment": "744 participants",
    Allocation: "Randomized",
    "Intervention Model": "Parallel Assignment",
    Masking:
      "Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
    "Primary Purpose": "Prevention",
    "Official Title":
      "A Randomized, Double-Blinded, Placebo-Controlled, Phase \u2160/\u2161 Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years",
    "Actual Study Start Date": "April 16, 2020",
    "Estimated Primary Completion Date": "August 13, 2020",
    "Estimated Study Completion Date": "December 13, 2020"
  },
  {
    "Trial Number": "NCT04324606",
    Developer:
      "Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., and Merck KGaA",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Estimated\r\nEnrollment": "1112 participants",
    Allocation: "Randomized",
    "Intervention Model": "Sequential Assignment",
    Masking: "Single (Participant)",
    "Primary Purpose": "Treatment",
    "Official Title":
      "A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers",
    "Estimated Study Start Date": "April 2020",
    "Estimated Primary Completion Date": "May 2021",
    "Estimated Study Completion Date": "May 2021"
  },
  {
    "Trial Number": "NCT04313127",
    Developer: "CanSino Biologics/Beijing Institute of Biotechnology",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Actual\r\nEnrollment": "108 participants",
    Allocation: "Non-Randomized",
    "Intervention Model": "Sequential Assignment",
    Masking: "None (Open Label)",
    "Primary Purpose": "Prevention",
    "Official Title":
      "A Single-center,Open-label\uff0cDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",
    "Actual Study Start Date": "March 16, 2020",
    "Estimated Primary Completion Date": "December 30, 2020",
    "Estimated Study Completion Date": "December 20, 2022"
  },
  {
    "Trial Number": "NCT04283461",
    Developer: "Moderna / NIAID",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Estimated\r\nEnrollment": "45 participants",
    Allocation: "Non-Randomized",
    "Intervention Model": "Sequential Assignment",
    Masking: "None (Open Label)",
    "Primary Purpose": "Prevention",
    "Official Title":
      "Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",
    "Actual Study Start Date": "March 3, 2020",
    "Estimated Primary Completion Date": "June 1, 2021",
    "Estimated Study Completion Date": "June 1, 2021"
  },
  {
    "Trial Number": "NCT04276896",
    Developer: "Shenzhen Geno-Immune Medical Institute",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Estimated\r\nEnrollment": "100 participants",
    "Intervention Model": "Single Group Assignment",
    Masking: "None (Open Label)",
    "Primary Purpose": "Treatment",
    "Official Title":
      "Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus",
    "Estimated Study Start Date": "March 24, 2020",
    "Estimated Primary Completion Date": "July 31, 2023",
    "Estimated Study Completion Date": "December 31, 2024"
  },
  {
    "Trial Number": "NCT04299724",
    Developer: "Shenzhen Geno-Immune Medical Institute",
    "Study Type": "Interventional\r\n                \u00a0(Clinical Trial)",
    "Estimated\r\nEnrollment": "100 participants",
    "Intervention Model": "Single Group Assignment",
    Masking: "None (Open Label)",
    "Primary Purpose": "Treatment",
    "Official Title":
      "Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine",
    "Actual Study Start Date": "February 15, 2020",
    "Estimated Primary Completion Date": "July 31, 2023",
    "Estimated Study Completion Date": "December 31, 2024"
  }
];

export default data;
